COVID-19

BioNTechs headquarters
Biotech

BioNTech pays $200M to license OncoC4's mid-stage antibody

BioNTech is paying $200 million upfront to license OncoC4's monoclonal antibody aimed at solid tumors, furthering the former's clinical cancer work.
Max Bayer Mar 20, 2023 11:15am
An artists rendering of the BQ 11 variant of COVID-19

Immunome decides not to top up its COVID antibody cocktail

Mar 16, 2023 10:05am
Graphic images of staff members falling off a conveyor belt representing layoffs

Vaxart cans oral COVID-19 vaccine plans, lays off 27% of staff

Mar 16, 2023 6:15am
FDA stop sign

FDA defends delayed EUA for Lucira's combo COVID/flu test

Mar 13, 2023 10:13am
graphic of someone pulling a large coronavirus representative of the virus being burdensome

FDA issues first full clearance for a rapid antigen COVID test

Mar 9, 2023 11:04am
change direction new plan alter arrows move reprioritize

Invivyd evolves yet again to keep pace with COVID-19

Mar 6, 2023 10:45am
More News

Veru's EUA ambitions for its COVID treatment crash

Mar 3, 2023 11:17am

FDA issues first EUA to over-the-counter COVID and flu test

Feb 27, 2023 10:01am

'We beg you': Biotechs plead for help with long COVID research

Feb 22, 2023 11:20am

Medtronic slows sales slip with flat revenues in Q3

Feb 21, 2023 3:05pm